Kantarjian HM - Search Results

1

A Systematic Review of the Cost-Effectiveness of Stereotactic Radiation Therapy for Cancer Oligometastases.

Verma V, Yegya-Raman N, Sprave T, Han G, Kantarjian HM, Welsh JW, Chang JY, Lin SH. Verma V, et al. Among authors: kantarjian hm. Int J Radiat Oncol Biol Phys. 2022 Dec 1;114(5):977-988. doi: 10.1016/j.ijrobp.2022.05.042. Epub 2022 Jun 5. Int J Radiat Oncol Biol Phys. 2022. PMID: 35675852 Review.

2

Comprehensive craniospinal radiation for controlling central nervous system leukemia.

Walker GV, Shihadeh F, Kantarjian H, Allen P, Rondon G, Kebriaei P, O'Brien S, Kedir A, Said M, Grant JD, Thomas DA, Gidley PW, Arzu I, Pinnix C, Reed V, Dabaja BS. Walker GV, et al. Int J Radiat Oncol Biol Phys. 2014 Dec 1;90(5):1119-25. doi: 10.1016/j.ijrobp.2014.08.004. Int J Radiat Oncol Biol Phys. 2014. PMID: 25539370 Free PMC article.

3

Toward Individualized Therapy in Acute Myeloid Leukemia: A Contemporary Review.

Kadia TM, Ravandi F, Cortes J, Kantarjian H. Kadia TM, et al. JAMA Oncol. 2015 Sep;1(6):820-8. doi: 10.1001/jamaoncol.2015.0617. JAMA Oncol. 2015. PMID: 26181162 Review.

4

Association of Measurable Residual Disease With Survival Outcomes in Patients With Acute Myeloid Leukemia: A Systematic Review and Meta-analysis.

Short NJ, Zhou S, Fu C, Berry DA, Walter RB, Freeman SD, Hourigan CS, Huang X, Nogueras Gonzalez G, Hwang H, Qi X, Kantarjian H, Ravandi F. Short NJ, et al. JAMA Oncol. 2020 Dec 1;6(12):1890-1899. doi: 10.1001/jamaoncol.2020.4600. JAMA Oncol. 2020. PMID: 33030517 Free PMC article.

5

Treatment of Adults With Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia-From Intensive Chemotherapy Combinations to Chemotherapy-Free Regimens: A Review.

Jabbour E, Haddad FG, Short NJ, Kantarjian H. Jabbour E, et al. JAMA Oncol. 2022 Sep 1;8(9):1340-1348. doi: 10.1001/jamaoncol.2022.2398. JAMA Oncol. 2022. PMID: 35834222 Review.

6

Failure of hypomethylating agent-based therapy in myelodysplastic syndromes.

Kadia TM, Jabbour E, Kantarjian H. Kadia TM, et al. Semin Oncol. 2011 Oct;38(5):682-92. doi: 10.1053/j.seminoncol.2011.04.011. Semin Oncol. 2011. PMID: 21943675 Free PMC article. Review.

7

Biosimilar and generic cancer drugs unlikely to bend cost curve in the USA.

Bennett CL, Sartor OA, Armitage JO, Kantarjian H. Bennett CL, et al. Lancet Oncol. 2017 Jan;18(1):22-23. doi: 10.1016/S1470-2045(16)30653-2. Lancet Oncol. 2017. PMID: 28049571 No abstract available.

8

Treatment value of second-generation BCR-ABL1 tyrosine kinase inhibitors compared with imatinib to achieve treatment-free remission in patients with chronic myeloid leukaemia: a modelling study.

Shih YT, Cortes JE, Kantarjian HM. Shih YT, et al. Among authors: kantarjian hm. Lancet Haematol. 2019 Aug;6(8):e398-e408. doi: 10.1016/S2352-3026(19)30087-0. Epub 2019 Jun 14. Lancet Haematol. 2019. PMID: 31208943 Free PMC article.

9

Impact of frontline treatment approach on outcomes of myeloid blast phase CML.

Saxena K, Jabbour E, Issa G, Sasaki K, Ravandi F, Maiti A, Daver N, Kadia T, DiNardo CD, Konopleva M, Cortes JE, Yilmaz M, Chien K, Pierce S, Kantarjian H, Short NJ. Saxena K, et al. J Hematol Oncol. 2021 Jun 15;14(1):94. doi: 10.1186/s13045-021-01106-1. J Hematol Oncol. 2021. PMID: 34130720 Free PMC article.

10

Myeloid lineage switch in KMT2A-rearranged acute lymphoblastic leukemia treated with lymphoid lineagedirected therapies.

Bataller A, Abuasab T, McCall D, Wang W, Cuglievan B, Issa GC, Jabbour E, Short N, DiNardo CD, Tang G, Garcia-Manero G, Kantarjian HM, Sasaki K. Bataller A, et al. Among authors: kantarjian hm. Haematologica. 2024 Jan 1;109(1):293-297. doi: 10.3324/haematol.2023.283705. Haematologica. 2024. PMID: 37646654 Free PMC article. No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

1,843 results

Search Page